insights_auto
Why is KYNB down 2.90%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
$6.70
arrow_downward
-2.90%(-0.20) 1D
Sep 29, 2:51:20 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$6.80
High
$6.95
Low
$6.66
Mkt. cap
27.13M
Avg. vol.
24.91K
Volume
6.39K
P/E ratio
0.15
52-wk high
$9.70
52-wk low
$6.32
EPS
$45.30
Beta
1.06
Shares outstanding
4.05M
No. of employees
34
Open
$6.80
High
$6.95
Low
$6.66
Mkt. cap
27.13M
Avg. vol.
24.91K
Volume
6.39K
P/E ratio
0.15
52-wk high
$9.70
52-wk low
$6.32
EPS
$45.30
Beta
1.06
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
AD HOC NEWS
·
1 day ago
FibroGen stock trades at USD 6.94 after Kyntra Bio rebrand
https://www.dars.gov.et/
·
2 months ago
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares - Quarterly Financial Update
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitekyntrabio.com